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Editorial on the Research Topic
IL-1 Family Members in Health and Disease
In 1985, two distinct cDNAs encoding proteins sharing human Interleukin-1 (IL-1) activity were
described, thus defining the first two members of the IL-1 family—IL-1α and IL-1β. These potent
pro-inflammatory cytokines have been the subject of much research in the area of fever and
inflammation, as well as for their roles in a myriad of inflammatory associated diseases. Over the
years the family expanded to include cytokines with both pro- and anti- inflammatory properties,
including IL-18, IL-33, IL-36, IL-37, IL-38, IL-1 receptor antagonist (IL-1Ra), and IL-36Ra. In
addition to the 11 identified cytokine members of this family, there are now multiple discrete
receptor family members, that form 4 functional receptor complexes able to activate downstream
signaling cascades, as well as several decoy and inhibitory receptors.
The inflammatory functions of these cytokines have been well-defined for the long established
family members but, in the case of some of the newermembers such as IL-36, IL-37, and IL-38, their
physiological roles are still being elucidated. For the pro-inflammatory cytokines, their primary
functions involve activating signaling cascades and mediating the inflammatory response to a wide
variety of signals, thereby co-ordinating innate and adaptive immune responses. To achieve this,
the IL-1 family cytokine binds to its cognate receptor which, in the case of all family members, then
causes recruitment of a specific accessory receptor. This interaction then allows for recruitment
of the signaling adaptor protein MyD88, the common adaptor to all family members. MyD88
engagement to the receptor complex subsequently results in the activation of the downstream
kinases, the IRAK family of proteins. Ultimately, through recruitment and activation of additional
signaling intermediates, key transcription factors, such as AP-1 and NFκB, become activated
translocate to the nucleus and result in transcription of a myriad of immune and inflammatory
genes. The importance of these protein:protein interactions and this pathway has long been
understood to hold the key to regulation of inflammation by IL-1 family members.
As is well-known, however “with great power comes great responsibility.” Therefore, given the
ability of IL-1 family members to so potently drive and upregulate the inflammatory response, it
is possibly not surprising that in recent years many members of this family have been identified as
being critical for the development of diverse inflammatory and allergic diseases with much work
focusing on IL-1 itself. Elevated plasma levels of IL-1, together with data from in vitro studies
and murine models, have resulted in an association of IL-1 with an array of auto-inflammatory
and autoimmune diseases. Perhaps the most illuminating data on the importance of IL-1 in
the exacerbation of disease states has been gained from studies inhibiting the mechanism of
action of these cytokines. Autoinflammatory conditions such as familial Mediterranean fever are
characterized by recurrent bouts of fever in conjunction with debilitating local and systemic
inflammation. These have proven to be responsive to IL-1β inhibition following administration
of the naturally occurring IL-1 Receptor antagonist (IL-1Ra). Similarly, administration of IL-1Ra
(now known by its generic name of anakinra) or administration of mAbs developed to target
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IL-1beta such as canikinumab, have also exhibited therapeutic
efficacy in a range of diseases including type-2 diabetes,
gout and rheumatoid arthritis. Indeed anakinra is now
an approved therapy for the auto-inflammatory condition,
Cryopyrin-Associated Periodic Syndromes and the autoimmune
disease Rheumatoid arthritis, whilst canakinumab is an approved
therapy for numerous auto-inflammatory conditions. It seems
likely that in the coming years these therapies will be extended
as approved treatments for additional diseases, as the therapeutic
efficacy of targeting IL-1 in diseases ranging from neovascular
disease to cancer is now being demonstrated in clinical trials.
Indeed, as is highlighted by the recent findings from the
CANTOS trial, IL-1β inhibition provides protection from the
development of lung cancer.
The therapeutic potential of these familymembers is not solely
limited to IL-1. IL-18 has been linked with a multitude of disease
pathologies from retinal neovascular disease to inflammatory
bowel disease. In terms of therapeutic targeting of IL-18, there
is a current emphasis on inhibition of IL-18 function in type
2 diabetes, whilst the therapeutic benefit of activating IL-18 is
being explored for both cancer and neovascular retinal disease.
The function of IL-33, was first comprehensively explored in Th2
cells and asthma, given the high level of expression of its receptor
in these cells, but has since been linked to other pathological
conditions. To date however, therapeutic manipulation of IL-33
is still mainly centered around its role in asthma and allergic
disease, with recent reports from a phase 2 clinical trial run
by Regeneron and Sanofi demonstrating positive results for
treatment of asthma with inhibition of IL-33. Like IL-1, IL-18,
and IL-33, the more recently characterized IL-36 similarly plays
a role in a variety of inflammatory diseases. Over activity of
IL-36, has been implicated in psoriasis with negative outcomes.
In contrast, administration of IL-36 in murine cancer models
appears to be efficacious in the reduction of tumor growth. Phase
1 clinical trials targeting IL-36 signaling in a rare form of psoriasis
(general pustular psoriasis) have shown positive results with this
compound now progressing to phase 2. The role of IL-37 is the
least understood with both pro and anti-inflammatory functions
assigned to it.
In fact, opposing functions for many in this cytokine family
have been shown, and as such it is clear that caution will have
to be exercised with respect to the ongoing development of
drugs targeting this family. Whereas, both IL-18 and IL-36 have
demonstrated clear roles in the pathogenesis of certain auto-
immune conditions, both have been seen to play a positive
role in cancer. Additionally, both IL-1 α and IL-33 function as
extracellular cytokines and as nuclear transcription factors, with
their roles in the nucleus still poorly understood, Targeting of
these cytokines therefore, may cause significant unwanted by-
stander effects meaning that drug development will need to be
nuanced to avoid unwanted interference in homeostatic roles.
Therefore, while this family of cytokines appears to present
excellent targets for many diseases, continued study and a
deeper understanding of the pleiotropy of their functions is
required. The substantial impact that drugs targeting this family
of cytokines have the potential to provide for human health
is evidenced by the sheer breadth of disease types that IL-
1 family cytokines regulate. This is highlighted in this special
topic and demonstrates that drugs developed to therapeutically
manipulate this family of cytokines have the potential to cast a
very wide net.
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